Skip to main content
Top
Published in: Journal of Diabetes & Metabolic Disorders 2/2023

24-09-2023 | Bariatric Surgery | Research article

Benefits in routinely measured liver function tests following bariatric surgery: a retrospective cohort study

Authors: Richard Roberts, David M Williams, Thinzar Min, Jonathan Barry, Jeffrey W Stephens

Published in: Journal of Diabetes & Metabolic Disorders | Issue 2/2023

Login to get access

Abstract

Background

Bariatric surgery is well-established to support long-term metabolic health benefits associated with considerable weight loss. Here, we aim to determine the longer-term impact of bariatric surgery on liver enzymes and associations with other metabolic improvements.

Methods

One hundred patients who underwent bariatric surgery between 2007 and 2014 were included, and changes in liver enzymes, anthropometric measures and other parameters were observed over a mean 9.8 years.

Results

At the time of surgery, the mean age was 45.4 ± 9.6 years, weight 141.2 ± 31.6 kg, and body mass index (BMI) 50.2 ± 10.1 kg/m2. Most patients underwent sleeve gastrectomy [n = 71] with a mean follow-up duration 9.8 ± 2.3 years. From baseline, alanine transaminase (ALT) reduced by 41.3% within 12 months post-operatively (36.6 ± 29.2 U/L to 21.5 ± 14.9 U/L, p < 0.001), which was sustained at recent follow-up (20.2 ± 10.7 U/L, p < 0.001). There were associated reductions in body weight, BMI, HbA1c, blood pressure and triglycerides. Patients with greater baseline ALT had the greatest reduction in ALT over follow-up.

Conclusions

Bariatric surgery is associated with rapid and sustained improvements in routine liver enzymes at 10 years, and sustained improvements in features of the metabolic syndrome.
Appendix
Available only for authorised users
Literature
1.
go back to reference Shah M, Simha V, Garg A. Long-term impact of bariatric surgery on Body Weight, Comorbidities, and Nutritional Status. J Clin Endocrinol Metab. 2006;91:4223–31.CrossRefPubMed Shah M, Simha V, Garg A. Long-term impact of bariatric surgery on Body Weight, Comorbidities, and Nutritional Status. J Clin Endocrinol Metab. 2006;91:4223–31.CrossRefPubMed
2.
go back to reference Kaul A, Sharma J. Impact of bariatric surgery on comorbidities. Surg Clin North Am. 2011;91:1295–312.CrossRefPubMed Kaul A, Sharma J. Impact of bariatric surgery on comorbidities. Surg Clin North Am. 2011;91:1295–312.CrossRefPubMed
4.
go back to reference Khosravi-Largani M, Nojomi M, Aghili R, Otaghvar HA, Tanha K, Seyedi SHS, et al. Evaluation of all types of metabolic bariatric surgery and its Consequences: a systematic review and Meta-analysis. Obes Surg. 2019;29:651–90.CrossRefPubMed Khosravi-Largani M, Nojomi M, Aghili R, Otaghvar HA, Tanha K, Seyedi SHS, et al. Evaluation of all types of metabolic bariatric surgery and its Consequences: a systematic review and Meta-analysis. Obes Surg. 2019;29:651–90.CrossRefPubMed
5.
go back to reference Głuszyńska P, Lemancewicz D, Dzięcioł JB, Razak Hady H. Non-alcoholic fatty liver Disease (NAFLD) and Bariatric/Metabolic surgery as its treatment option: a review. J Clin Med. 2021;10:5721.CrossRefPubMedPubMedCentral Głuszyńska P, Lemancewicz D, Dzięcioł JB, Razak Hady H. Non-alcoholic fatty liver Disease (NAFLD) and Bariatric/Metabolic surgery as its treatment option: a review. J Clin Med. 2021;10:5721.CrossRefPubMedPubMedCentral
6.
7.
go back to reference Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al. Nonalcoholic Steatohepatitis Clinical Research Network. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41:1313–21.CrossRefPubMed Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al. Nonalcoholic Steatohepatitis Clinical Research Network. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41:1313–21.CrossRefPubMed
8.
go back to reference Kontrick AV, VanWagner LB, Yeh C, Courtney DM. Hepatic steatosis: an Incidental Finding that deserves attention. Acad Emerg Med. 2021;28:578–81.CrossRefPubMed Kontrick AV, VanWagner LB, Yeh C, Courtney DM. Hepatic steatosis: an Incidental Finding that deserves attention. Acad Emerg Med. 2021;28:578–81.CrossRefPubMed
9.
go back to reference Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology. 1999;116:1413–9.CrossRefPubMed Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology. 1999;116:1413–9.CrossRefPubMed
10.
go back to reference Dhanasekaran R, Felsher DW. A tale of two complications of obesity: nonalcoholic steatohepatitis (NASH) and hepatocellular carcinoma (HCC). Hepatology 2019;70:1056–8. Dhanasekaran R, Felsher DW. A tale of two complications of obesity: nonalcoholic steatohepatitis (NASH) and hepatocellular carcinoma (HCC). Hepatology 2019;70:1056–8.
11.
go back to reference Eguchi Y, Wong G, Lee IH, Akhtar O, Lopes R, Sumida Y. Hepatocellular carcinoma and other complications of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in Japan: a structured review of published works. Hepatol Res. 2021;51:19–30.CrossRefPubMed Eguchi Y, Wong G, Lee IH, Akhtar O, Lopes R, Sumida Y. Hepatocellular carcinoma and other complications of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in Japan: a structured review of published works. Hepatol Res. 2021;51:19–30.CrossRefPubMed
12.
go back to reference Witkowski M, Moreno SI, Fernandes J, Johansen P, Augusto M, Nair S. The Economic Burden of non-alcoholic steatohepatitis: a systematic review. PharmacoEconomics. 2022;40:751–76.CrossRefPubMedPubMedCentral Witkowski M, Moreno SI, Fernandes J, Johansen P, Augusto M, Nair S. The Economic Burden of non-alcoholic steatohepatitis: a systematic review. PharmacoEconomics. 2022;40:751–76.CrossRefPubMedPubMedCentral
13.
go back to reference Machado M, Marques-Vidal P, Cortez-Pinto H. Hepatic histology in obese patients undergoing bariatric surgery. J Hepatol. 2006;45:600–6.CrossRefPubMed Machado M, Marques-Vidal P, Cortez-Pinto H. Hepatic histology in obese patients undergoing bariatric surgery. J Hepatol. 2006;45:600–6.CrossRefPubMed
14.
go back to reference Tamaki N, Ajmera V, Loomba R. Non-invasive methods for imaging hepatic steatosis and their clinical importance in NAFLD. Nat Rev Endocrinol. 2022;18:55–66.CrossRefPubMed Tamaki N, Ajmera V, Loomba R. Non-invasive methods for imaging hepatic steatosis and their clinical importance in NAFLD. Nat Rev Endocrinol. 2022;18:55–66.CrossRefPubMed
15.
go back to reference Alqahtani SA, Golabi P, Paik JM, Lam B, Moazez AH, Elariny HA, et al. Performance of Noninvasive Liver fibrosis tests in morbidly obese patients with nonalcoholic fatty liver disease. Obes Surg. 2021;31:2002–10.CrossRefPubMedPubMedCentral Alqahtani SA, Golabi P, Paik JM, Lam B, Moazez AH, Elariny HA, et al. Performance of Noninvasive Liver fibrosis tests in morbidly obese patients with nonalcoholic fatty liver disease. Obes Surg. 2021;31:2002–10.CrossRefPubMedPubMedCentral
16.
go back to reference Castera L. Non-invasive tests for liver fibrosis in NAFLD: creating pathways between primary healthcare and liver clinics. Liver Int. 2020;40:77–81.CrossRefPubMed Castera L. Non-invasive tests for liver fibrosis in NAFLD: creating pathways between primary healthcare and liver clinics. Liver Int. 2020;40:77–81.CrossRefPubMed
17.
go back to reference Palekar NA, Naus R, Larson SP, Ward J, Harrison SA. Clinical model for distinguishing nonalcoholic steatohepatitis from simple steatosis in patients with nonalcoholic fatty liver disease. Liver Int. 2006;26:151–6.CrossRefPubMed Palekar NA, Naus R, Larson SP, Ward J, Harrison SA. Clinical model for distinguishing nonalcoholic steatohepatitis from simple steatosis in patients with nonalcoholic fatty liver disease. Liver Int. 2006;26:151–6.CrossRefPubMed
19.
go back to reference Umeda LM, Silva EA, Carneiro G, Arasaki CH, Geloneze B, Zanella MT. Early improvement in glycemic control after bariatric surgery and its relationships with insulin, GLP-1, and glucagon secretion in type 2 diabetic patients. Obes Surg. 2011;21:896–901.CrossRefPubMed Umeda LM, Silva EA, Carneiro G, Arasaki CH, Geloneze B, Zanella MT. Early improvement in glycemic control after bariatric surgery and its relationships with insulin, GLP-1, and glucagon secretion in type 2 diabetic patients. Obes Surg. 2011;21:896–901.CrossRefPubMed
20.
go back to reference Salehi M, Prigeon RL, D’Alessio DA. Gastric bypass surgery enhances Glucagon-Like peptide 1–Stimulated postprandial insulin secretion in humans. Diabetes. 2011;60:2308–14.CrossRefPubMedPubMedCentral Salehi M, Prigeon RL, D’Alessio DA. Gastric bypass surgery enhances Glucagon-Like peptide 1–Stimulated postprandial insulin secretion in humans. Diabetes. 2011;60:2308–14.CrossRefPubMedPubMedCentral
21.
go back to reference Vigneshwaran B, Wahal A, Aggarwal S, Priyadarshini P, Bhattacharjee H, Khadgawat R, et al. Impact of Sleeve Gastrectomy on type 2 diabetes Mellitus, gastric emptying Time, Glucagon-Like peptide 1 (GLP-1), Ghrelin and Leptin in Non-morbidly obese subjects with BMI 30–35.0 kg/m2: a prospective study. Obes Surg. 2016;26:2817–23.CrossRefPubMed Vigneshwaran B, Wahal A, Aggarwal S, Priyadarshini P, Bhattacharjee H, Khadgawat R, et al. Impact of Sleeve Gastrectomy on type 2 diabetes Mellitus, gastric emptying Time, Glucagon-Like peptide 1 (GLP-1), Ghrelin and Leptin in Non-morbidly obese subjects with BMI 30–35.0 kg/m2: a prospective study. Obes Surg. 2016;26:2817–23.CrossRefPubMed
23.
go back to reference Lee Y, Doumouras AG, Yu J, Brar K, Banfield L, Gmora S, et al. Complete resolution of nonalcoholic fatty liver Disease after bariatric surgery: a systematic review and Meta-analysis. Clin Gastroenterol Hepatol. 2019;17:1040–60.CrossRefPubMed Lee Y, Doumouras AG, Yu J, Brar K, Banfield L, Gmora S, et al. Complete resolution of nonalcoholic fatty liver Disease after bariatric surgery: a systematic review and Meta-analysis. Clin Gastroenterol Hepatol. 2019;17:1040–60.CrossRefPubMed
24.
go back to reference Aranda-Michel J, Sherman KE. Tests of the liver: use and misuse. Gastroenterologist. 1998;6:34–43.PubMed Aranda-Michel J, Sherman KE. Tests of the liver: use and misuse. Gastroenterologist. 1998;6:34–43.PubMed
25.
go back to reference Prati D, Taioli E, Zanella A, Della Torre E, Butelli S, Del Vecchio E, et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med. 2002;137:1–10.CrossRefPubMed Prati D, Taioli E, Zanella A, Della Torre E, Butelli S, Del Vecchio E, et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med. 2002;137:1–10.CrossRefPubMed
26.
go back to reference Lassailly G, Caiazzo R, Buob D, Pigeyre M, Verkindt H, Labreuche J, et al. Bariatric surgery reduces features of nonalcoholic steatohepatitis in morbidly obese patients. Gastroenterology. 2015;149:379–88.CrossRefPubMed Lassailly G, Caiazzo R, Buob D, Pigeyre M, Verkindt H, Labreuche J, et al. Bariatric surgery reduces features of nonalcoholic steatohepatitis in morbidly obese patients. Gastroenterology. 2015;149:379–88.CrossRefPubMed
27.
go back to reference Lassailly G, Caiazzo R, Ntandja-Wandji LC, Gnemmi V, Baud G, Verkindt H, et al. Bariatric surgery provides long-term resolution of nonalcoholic steatohepatitis and regression of fibrosis. Gastroenterology. 2020;159:1290–301.CrossRefPubMed Lassailly G, Caiazzo R, Ntandja-Wandji LC, Gnemmi V, Baud G, Verkindt H, et al. Bariatric surgery provides long-term resolution of nonalcoholic steatohepatitis and regression of fibrosis. Gastroenterology. 2020;159:1290–301.CrossRefPubMed
28.
go back to reference Lee Y, Doumouras AG, Yu J, Brar K, Banfield L, Gmora S, et al. Complete resolution of nonalcoholic fatty liver Disease after bariatric surgery: a systematic review and Meta-analysis. Clin Gastroenterol Hepatol. 2019;17:1040–60e11.CrossRefPubMed Lee Y, Doumouras AG, Yu J, Brar K, Banfield L, Gmora S, et al. Complete resolution of nonalcoholic fatty liver Disease after bariatric surgery: a systematic review and Meta-analysis. Clin Gastroenterol Hepatol. 2019;17:1040–60e11.CrossRefPubMed
29.
go back to reference Ma X, Liu S, Zhang J, Dong M, Wang Y, Wang M, et al. Proportion of NAFLD patients with normal ALT value in overall NAFLD patients: a systematic review and meta-analysis. BMC Gastroenterol. 2020;20:10.CrossRefPubMedPubMedCentral Ma X, Liu S, Zhang J, Dong M, Wang Y, Wang M, et al. Proportion of NAFLD patients with normal ALT value in overall NAFLD patients: a systematic review and meta-analysis. BMC Gastroenterol. 2020;20:10.CrossRefPubMedPubMedCentral
30.
go back to reference Chakhtoura MT, Nakhoul NN, Shawwa K, Mantzoros C, El Fuleihan H. Hypovitaminosis D in bariatric surgery: a systematic review of observational studies. Metabolism. 2016;65:574–85.CrossRefPubMed Chakhtoura MT, Nakhoul NN, Shawwa K, Mantzoros C, El Fuleihan H. Hypovitaminosis D in bariatric surgery: a systematic review of observational studies. Metabolism. 2016;65:574–85.CrossRefPubMed
32.
33.
go back to reference Assmann G, Schulte H. The importance of triglycerides: results from the prospective cardiovascular Münster (PROCAM) study. Eur J Epidemiol. 1992;8:99–103.CrossRefPubMed Assmann G, Schulte H. The importance of triglycerides: results from the prospective cardiovascular Münster (PROCAM) study. Eur J Epidemiol. 1992;8:99–103.CrossRefPubMed
34.
go back to reference Farhangi MA, Nikniaz L, Nikniaz Z. Higher dietary acid load potentially increases serum triglyceride and obesity prevalence in adults: an updated systematic review and meta-analysis. PLoS ONE. 2019;14:e0216547.CrossRef Farhangi MA, Nikniaz L, Nikniaz Z. Higher dietary acid load potentially increases serum triglyceride and obesity prevalence in adults: an updated systematic review and meta-analysis. PLoS ONE. 2019;14:e0216547.CrossRef
35.
go back to reference Mazzini GS, Augustin T, Noria S, Romero-Marrero C, Li N, Hameed B, et al. ASMBS position Statement on the impact of metabolic and bariatric surgery on nonalcoholic steatohepatitis. Surg Obes Relat Dis. 2022;18:314–25.CrossRefPubMed Mazzini GS, Augustin T, Noria S, Romero-Marrero C, Li N, Hameed B, et al. ASMBS position Statement on the impact of metabolic and bariatric surgery on nonalcoholic steatohepatitis. Surg Obes Relat Dis. 2022;18:314–25.CrossRefPubMed
Metadata
Title
Benefits in routinely measured liver function tests following bariatric surgery: a retrospective cohort study
Authors
Richard Roberts
David M Williams
Thinzar Min
Jonathan Barry
Jeffrey W Stephens
Publication date
24-09-2023
Publisher
Springer International Publishing
Published in
Journal of Diabetes & Metabolic Disorders / Issue 2/2023
Electronic ISSN: 2251-6581
DOI
https://doi.org/10.1007/s40200-023-01311-4

Other articles of this Issue 2/2023

Journal of Diabetes & Metabolic Disorders 2/2023 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine